# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-03-10T14:28:02.028850
**Route:** Direct Google API + PDF
**Paper Hash:** cb13bcbf20050003
**Tokens:** 19878 in / 451 out
**Response SHA256:** b86d37d9ff18862c

---

I have reviewed the draft paper for fatal errors that would preclude submission to a journal.

**ADVISOR VERDICT: PASS**

### Review Summary:
I have checked the draft across the four critical categories and found no fatal errors.

1.  **Data-Design Alignment:** The paper studies the May 2018 REACH deadline using a sample that extends to 2020. The DDD design correctly uses pre-treatment intensity (2014–2017) to predict post-treatment outcomes. The RDD/event study figures correctly show data on both sides of the 2018 cutoff.
2.  **Regression Sanity:** 
    *   **Table 2:** $R^2$ values are between 0.988 and 0.997, which is expected and explained by the extensive set of interacted fixed effects. Coefficients for log outcomes are within a plausible range (0.1 to 0.7). Standard errors are proportionate to coefficients (e.g., Col 2: $-0.4507$ with $SE = 0.1705$).
    *   **Table 3:** The placebo check shows no "broken" outputs; coefficients and SEs are stable.
    *   **Table 8:** Standard errors remain consistent across size-class sub-samples.
3.  **Completeness:** All tables contain N (observations) and clustered standard errors. There are no placeholder values ("XXX", "TBD"). All referenced tables (Table 1 through Table 8) and figures (Figure 1 through Figure 9) are present in the text or appendix.
4.  **Internal Consistency:** Statistics cited in the abstract ($\hat{\beta} = -0.451, p = 0.014$) match the results in Table 2, Column 2. The description of pre-trends in the text (Section 5.2) is consistent with the visual evidence provided in Figure 3. The sample sizes (N) are consistent across the main results and the robustness tables.

ADVISOR VERDICT: PASS